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Abstract
Background: In vitro culture of pathogens on growth media forms a "pillar" for both infectious
disease diagnosis and drug sensitivity profiling. Conventional cultures of Mycobacterium tuberculosis
(M.tb) on Lowenstein Jensen (LJ) medium, however, take over two months to yield observable
growth, thereby delaying diagnosis and appropriate intervention. Since DNA duplication during
interphase precedes microbial division, "para-DNA synthesis assays" could be used to predict
impending microbial growth. Mycobacterial thymidylate kinase (TMKmyc) is a phosphotransferase
critical for the synthesis of the thymidine triphosphate precursor necessary for M.tb  DNA
synthesis. Assays based on high-affinity detection of secretory TMKmyc levels in culture using
specific antibodies are considered. The aim of this study was to define algorithms for predicting
positive TB cultures using antibody-based assays of TMKmyc levels in vitro.
Methods and results: Systems and chemical biology were used to derive parallel correlation of
"M.tb growth curves" with "TMKmyc curves" theoretically in four different scenarios, showing that
changes in TMKmyc levels in culture would in each case be predictive of M.tb growth through a
simple quadratic curvature, |tmk| = at2+ bt + c, consistent with the "S" pattern of microbial growth
curves. Two drug resistance profiling scenarios are offered: isoniazid (INH) resistance and
sensitivity. In the INH resistance scenario, it is shown that despite the presence of optimal doses
of INH in LJ to stop M.tb proliferation, bacilli grow and the resulting phenotypic growth changes in
colonies/units are predictable through the TMKmyc assay. According to our current model, the
areas under TMKmyc curves (AUC, calculated as the integral ∫(at2+ bt + c)dt or ~1/3 at3+ 1/2
bt2+ct) could directly reveal the extent of prevailing drug resistance and thereby aid decisions
about the usefulness of a resisted drug in devising "salvage combinations" within resource-limited
settings, where second line TB chemotherapy options are limited.
Conclusion: TMKmyc assays may be useful for reducing the time-lines to positive identification of
Mycobacterium  tuberculosis  (M.tb) cultures, thereby accelerating disease diagnosis and drug
resistance profiling. Incorporating "chemiluminiscent or fluorescent" strategies may enable "photo-
detection of TMKmyc changes" and hence automation of the entire assay.
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Background
Infection with Mycobacterium tuberculosis (M.tb), the caus-
ative agent of tuberculosis (TB), is one of the leading glo-
bal health challenges [1,2]. An estimated 8–10 million
persons acquire tuberculosis annually, 2 million of whom
die [1,2]. The global TB epidemic has been complicated by
the human immunodeficiency virus (HIV) co-epidemic
[3]. Interaction between HIV and TB: (i) is associated with
a higher risk of progression to active M. tuberculosis infec-
tion (ATBI) among persons with existing latent infection
(LTBI); (ii) leads to increased susceptibility to new infec-
tion with M.tb; (iii) renders diagnosis difficult and treat-
ment/cure rates slow; (iv) results in a higher incidence of
relapses; and (v) favors the evolution of drug resistance
[1,4-6]. Amongst these, the emergence of drug resistance
forms the deadliest challenge to controlling the TB epi-
demic. In HIV/TB high burden areas such as South Africa,
drug resistance has extended from the first line anti-TB
drugs to include the second line drugs spared for multi-
drug resistant (MDR) TB, XDR [7]. Early detection of TB
has a crucial role to play in controlling the epidemic here.
In the past, diagnosis has been based on prediction of
prior infection using the purified protein derivative
(PPD)-tuberculin skin test (TST), detecting active TB by
sputum smear staining using the Zeihl Neilson Stain (ZN)
or culturing the organism on Lowenstein Jensen (LJ)
medium; and radiographic imaging for TB-associated
pathology [8,9]. More recently, newer molecular assays
for TB have emerged based on serology (detecting the 38
kDa antigen, Early Secretory Antigen or ESAT-6, CFP10
and other secretory antigens), nucleic acid amplification
(NAATS), phage amplification and line probe assays for
MDR [10]. Despite the advent of these modern TB assays,
largely because there are no inexpensive technology plat-
forms exploiting related biomarkers, approaches based on
in vitro cultures still form the most reliable and readily
affordable method for diagnosing TB in many resource-
limited settings [10]. In general, in vitro culture of patho-
gens on appropriate growth media forms a "pillar" for
both infectious disease diagnosis and drug sensitivity pro-
filing [9].
Conventional cultures of the slowly-growing tubercle
bacilli (M.tb) on LJ medium, though highly sensitive for
TB [10], are nevertheless time-consuming since they take
about two months to yield observable growth, thereby
delaying disease diagnosis and appropriate intervention.
Although reading of culture results is still widely based on
physical observation of the formation of bacterial colo-
nies, modified assays that predict changes in 'in vitro M.tb
growth" by monitoring turbidity or metabolism of
labeled metabolites are occasionally used to confirm the
presence of actively growing tubercle bacilli [9-13] and to
characterize drug resistance [9,14-16]. Specifically, some
of these modified culture assays such as phage amplifica-
tion assays, line probe assays and colorimetric redox-indi-
cator methods can predict positive M.tb cultures (or drug
resistance) in shorter times than the stipulated 2–3
months of culture on unmodified LJ medium. Most of
these emerging TB assays are, however, still not readily
available for routine use in most resource-limited settings
where the TB burden is concurrently high [9]. We hypoth-
esized that metabolomic-based assays of "para-DNA
duplicative" changes during interphase could predict
impending M.tb  growth before actual growth occurs.
Moreover, easier platforms such as chemilumniscence or
fluorescence photodetection may be incorporated into
these bioassays, thereby making them more affordable
than the aforementioned existing methods for TB detec-
tion [10]. That hypothesis is derived from and based on
several biological principles of the cell cycle, which are
discussed below.
First, prokaryotic growth and proliferation, unlike that of
eukaryotes, is predominantly achieved through division
of single cells [17]. The period between the "birth" of two
daughter cells from the parent cell and their own division
is termed interphase. During interphase, cells undergo a
resting (S) phase during which, though little physical
activity is noted microscopically, DNA duplication occurs
[17]. Since DNA synthesis precedes actual microbial divi-
sion and proliferation, monitoring "DNA synthesis" may
predict microbial growth changes well before the visible
manifestation of actual microbial growth in culture.
Second, phosphorylation of deoxythymidine monophos-
phate (dTMP) is a critical step in the pathway leading to
the synthesis of thymidylate triphosphate (TTP), a neces-
sary precursor for DNA synthesis [18]. This process is cat-
alyzed by enzymes called kinases or phosphotransferases
[18]. Among mammalian cells, two phosphotransferases
exist: thymidine kinases (types 1 and 2) and thymidylate
kinase [18]. Sherley and Kelly have previously reported a
positive correlation between levels of human TK and DNA
duplicative changes in the cell cycle [19]. Within myco-
bacterial proteomes, however, no thymidine kinase has
been detected [18]. Instead, mycobacterial thymidylate
kinase (TMKmyc) carries out this critical phosphorylative
function [18]. From this knowledge base, we proposed
that levels of TMKmyc may similarly parallel DNA synthe-
sis during the M.tb cell cycle [18,19]. We recently focused
on research and development of an antibody-based
biomarker for TMKmyc. To date, we have identified
highly conserved surface linear peptides of TMKmyc as
potential B-cell immunogens for in situ engineering of
TMK-specific monoclonal antibodies (MAbs). Such TMK-
myc-specific MAb(s) could be used to monitor of levels of
TMKmyc in cultures of M.tb. In this paper, we attempt to
provide a theoretical framework upon which we propose
reduction of time-lines for positive identification andTheoretical Biology and Medical Modelling 2009, 6:4 http://www.tbiomed.com/content/6/1/4
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drug resistance profiling among Mycobacterium tubercu-
losis (M. tb) cultures using thymidylate kinase (TMK)
assays.
Methods and results
1. Arithmetical derivations of the systems biology of the 
tubercle bacillus growth curve
(a) Theoretical partition of the tubercle bacillus cell cycle
We partitioned a "model" cell cycle of the tubercle bacil-
lus, according each phase (G1, S, G2 and M) a time line
[17]. These still ambiguous times have been designated: ts
= time taken by the parent cell in the S phase; t(s+G2) = time
taken for completion of a single 'cycle of the central
dogma', i.e from DNA synthesis to protein expression;
and t(G1+s+G2) = generation time of a tubercle bacillus (see
Fig. 1). These are likely to vary from one cell type to
another.
(b) Tubercle bacillus growth curve patterns and biometric algorithms
As for all microbes, we assumed that the growth of tuber-
cle bacilli follows the same "S" pattern, characterized by
an initial "slow growth" phase, then an exponential phase
and finally a stationary stage. The arithmetic of "S" curves
is largely quadratic, the relationship between number of
colonies per unit (μ) at any time (t) being stated as a deriv-
ative of the equation μ = at2+ bt + c (see Fig. 2). From this
equation, we infer that the constants c, b and a respec-
tively represent: c = the number of viable cells in the initial
inoculum; b = the number of actively growing cells during
the slow growth phase; and a = the cell division (or turn-
over) rate during exponential phase.
2. Geometric correlation of TMKmyc levels with the M.tb 
growth curve
We employed systems and chemical biology models to
parallel "M.tb growth curves" theoretically with "TMKmyc
curves" in four different scenarios. First, we assumed that
the level of TMKmyc within an M.tb culture is equal to the
total TMKmyc produced by all the functionally viable cel-
lular units within all the colonies in vitro. This assumption
was aimed at minimizing the impact of heterogeneity
within the culture, which may contain an admixture
(quasi) of dividing and non-dividing M.tb. Basically, as
long as overall proliferation occurs, the cumulative levels
of TMK would rise in proportion. Second, assuming that
DNA synthesis occurs 2, 4, 6 and 8 days after inoculation
(and that these are the equivalent time-lines for the G1
phase, tG1); then a further 58, 56, 54 and 52 days would
be required for actual division of the tubercle bacilli to
occur. Therefore, M.tb  DNA synthesis may parallel the
actual growth of tubercle bacilli but occur at a much ear-
lier time. Hence the total secreted levels of enzymes such
as TMKmyc synthesized during the cell cycle may parallel
the "S" pattern of the microbial growth curve (and equally
obey the quadratic equation); except that these changes
are bound to occur much earlier.
Overall, assuming that the cumulative levels of tmk in the
culture is the total tmk derived from the individual cells in
the culture, then, as for the microbial growth curves, it is
highly probable that TMKmyc levels will obey an "S" pat-
tern consistent with quadratic equations, but one that is
manifest earlier. The levels of tmk per unit (|tmk|) at any
time (t) on this gradient may therefore be represented as
the product of the equation |tmk| = at2+ bt + c, where a, b
and c are constants (possibly representing: a = multiple of
the levels of TMPKmyc required to salvage a mole of
dTMP during the exponential phase of M.tb growth; b =
factor of levels of TMKmyc required to phosphorylate
dTMP during the initial slow growth phase; and c = level
of tmk required to phosphorylate a single dTMP molecule
within the initial inoculum when no active division is
ongoing) (see Fig. 3).
The tubercle bacillus cell cycle Figure 1
The tubercle bacillus cell cycle. The figure offers a 
graphic illustration of the cell cycle of the tubercle bacillus 
partitioned into the S (stationery or synthetic), G and M 
(mitotic) phases. Note that the times ts, t(s+G2) and 
t(G1+s+G2) are in a practical sense unknown.
dC1
  G1ĺ      Sĺ G 2ĺ M ĺ
dC2
            <__ts__>
            <_____t(s+G2)____>
<_______________t (G1+s+G2)_______>
A theorized tubercle bacillus growth curve (colonies per unit  against time in months) Figure 2
A theorized tubercle bacillus growth curve (colonies 
per unit against time in months). The figure shows the 
typical S pattern characteristic of the growth of microbes in 
culture. Note the existence of an initial slow growth phase, 
followed by an exponential stage and finally a stationary 
phase.
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3. Prediction of drug sensitivity profiles based on TMKmyc 
levels rather than observation of M.tb growth changes 
(colonies per unit)
Two drug resistance profiling scenarios were modelled,
isoniazid (INH) resistance and sensitivity. In the INH
resistance scenario, we projected that although the dose of
INH in LJ is optimal for stopping M.tb  proliferation,
tubercle bacilli will continue to grow. Because the time-
line for observing these growth changes (colonies/unit) is
long, we believe that predictions of such growth changes
based on TMKmyc assays (which parallel growth changes
but occur earlier) may be a relatively quick way of deter-
mining drug resistance. In the INH sensitive scenario,
since the drug inhibits or slows microbial growth, these
changes may equally be predicted by TMKmyc levels
recorded in the presence of the drug (growth is bound to
be absent or at least much lower than in the absence of
drug or in the drug resistance scenario) (see Fig. 4A and 4B
for illustrations of INH sensitive and resistant scenarios
respectively).
Discussion
This paper provides the first ever theoretical and modeling
framework to support the view that assays of enzymes
involved in the synthesis of DNA precursors may be
applied to shorten the time-lines to positive identification
of microbial cultures (and possibly of other cell lines
including cancers). Specifically: if variations in TMKmyc
during the S phase of the tubercle bacillus cell cycle are
independent of the time taken by the tubercle in other
stages of the cycle, then TMKmyc assays are a potential
Predicted pattern of TMKmyc variation in M.tb cultures Figure 3
Predicted pattern of TMKmyc variation in M.tb cul-
tures. This figure aims to illustrate the predicted pattern of 
variation in TMKmyc levels with the cell cycle, assuming that 
(1) levels of TMKmyc parallel growth changes and (2) DNA 
synthesis occurs 2–6 days after inoculation of the sample on 
LJ medium.
Projected patterns of variation of TMKmyc curves in the drug sensitive and resistance scenario against a normal TMKmyc  curve Figure 4
Projected patterns of variation of TMKmyc curves in the drug sensitive and resistance scenario against a nor-
mal TMKmyc curve. This figure shows theorized patterns of variation for TMKmyc curves in the drug sensitive (A) and 
resistance (B) scenarios against a background normal TMKmyc curve. Note that, from this illustration, one could say that the 
extent of resistance (or number of mutant phenotypes) present in scenario B is the difference between the areas under both 
curves shaded light yellow. Note also that for any drug resistance profiling based on tmk assays, resistance may be viewed as 
inversely correlated to TMKmyc levels, while sensitivity is directly proportional to levels of TMK. The difference between 
TMKmyc levels of test versus standard TMKmyc curve is denoted by a window "wj" or wayengera-joloba lag, the numerical 
value of which is "WJ". Overall, drug sensitivity ~WJ and resistance ~1/WJ.Theoretical Biology and Medical Modelling 2009, 6:4 http://www.tbiomed.com/content/6/1/4
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predictive biomarker of in vitro M.tb growth that may be
applied to reducing the time-lines to positive identifica-
tion of Mycobacterium tuberculosis (M.tb) cultures. There
are several existing methods for detecting TB within cul-
tures, but they mostly lack inexpensive platforms for rou-
tine use within resource-limited settings where the TB
burden is highest [10]. Moreover, many of these emerging
TB assays [10] are not specific for detecting duplicative
changes in M.tb DNA. We therefore felt it necessary to
establish a highly specific M.tb DNA duplicative assay that
may be mounted on inexpensive technology platforms
that are currently widely used within resource-limited set-
tings, such as lateral flow immunochromatography.
Overall, tmk-based assays are therefore likely to be cheap
but still serve the purpose of accelerating diagnosis and
drug resistance profiling of M.tb and possibly other infec-
tious diseases in culture. First, we show here why varia-
tions in the durations of the G1, S and G2 phases of the
M.tb cell cycle may account for a longer 'culture time' for
M.tb (see Fig. 1 for illustration) than for other microbes.
In principle, the generation time of any cell is determined
by the time it spends in G1 and G2 [17]. Some cells, how-
ever, are known to go into deeper states of latency or dor-
mancy (designated G0 or even G00), only reverting to the
G1 stage when a need for reproduction, proliferation or
regeneration arises [17]. Various environmental factors
are known to initiate such deeper states of dormancy in
microbes and eukaryotes alike including low temperature,
absence of nutrients and low oxygenation states [20];
though the full range of factors that determine why tuber-
cle bacilli go into related states of latency in vivo are yet to
be fully established [1,21]. It is therefore unclear whether
these deeper states of dormancy explain the slowly-grow-
ing nature of M.tb (especially since host immune factors
also seem to play a significant role in arresting M.tb prolif-
eration in vivo [21]). What is evident from our theoretical
models, though, is that experiments aimed at establishing
the actual values of the durations tG1, ts and tG2 for various
microbes including M.tb may yield significant knowledge
about the rate-limiting steps in their "growth" activity
when cultured. For instance, using our proposed TMKmyc
antigen capture assays, together with radio-labeled phos-
phorylated (dTMPr) nucleotide bases as metabolites, the
time ts required for DNA duplication by the tubercle bacil-
lus may be estimated.
Second, from the theoretical model that the timeline for
the G1 phase of the M.tb cell cycle (tG1) is constant at 2, 4,
6 or 8 days, we inferred a parallel correlation of tubercle
bacillus "growth changes" with TMK levels in each sce-
nario (although changes in TMKmyc levels were predicted
to occur much earlier, as noted in Figure 3B). These pre-
dictions are based on the hypothesis that since DNA syn-
thesis precedes all cellular division, and TMKmyc is
required to create the dTTP necessary for DNA synthesis,
monitoring the levels of TMKmyc may predict actual
growth changes well before such changes occur. Note,
however, that the actual durations of the constituent
phases of the M.tb cell cycle remain uncertain as stated
above. One may therefore be justified in arguing that this
presumption regarding the timing of the G1 phase of the
M.tb cell cycle at days 2, 4,.... etc. is currently speculative,
given that it is not yet clear which of the two stages, G1 or
G2, constitutes the larger proportion of the generation
time of the tubercle bacillus (see Fig. 2 and 3). Neverthe-
less, using this arbitrary presumption that DNA synthesis
may occur only days after inoculation and that it is the G2
phase rather than G1 that accounts for much of the delay
in physical manifestation of M.tb growth changes in cul-
ture, we show here that TMKmyc assays could predict TB
growth in vitro as early as day 2 of culture. Moreover, we
have successfully used it here to theorize that TMKmyc
assays may also be exploited to distinguish drug-sensitive
from – resistant forms of tuberculosis in culture (see Fig.
4). In this context, those test samples with evident rises in
TMKmyc levels would in a practical sense be resistant to
the drug being tested, whereas isolates where TMKmyc
levels fail to rise are sensitive. From the graphs 4 A and B,
one equally notes that: (1) tubercle bacillus drug sensitiv-
ity is an inverse factor of TMKmyc while existing resistance
profiles are directly correlated to TMKmyc levels; (2) by
measuring and quantifying the comparative difference
between the areas under the TMKmyc curves (AUC) of
resistant and sensitive isolates, it may be possible to quan-
tify the existing levels of resistance (or number of resistant
mutants). Assuming that the difference between TMKmyc
levels in stationary phase between the tested M.tb isolates
and the standard tmk curve is arbitrarily denoted a win-
dow "wj" of which the numerical value is "WJ"; then:
Drug sensitivity ~WJ (1)
Drug Resistance ~1/WJ (2)
Note that in equations I and II representing tmk variation
in sensitive and resistant M.tb  isolate scenarios respec-
tively; the |tmk| levels within the test isolate culture are
inversely correlated to the numerical value of the way-
engera-joloba lag or "wj" window, also denoted "WJ".
The above Area Under Curve (AUC) method for drug
resistance profiling offers a means of quantifying drug
resistance. Such ability to quantify resistance is especially
clinically significant within resource-limited settings
where second-line TB chemotherapy options are limited
and drugs with minimal evident resistance are useful in
combination with other drugs to which the isolate being
treated is not resistant. In other words, TMK assays would
enable the derivation of "salvage" regimens from the lim-Theoretical Biology and Medical Modelling 2009, 6:4 http://www.tbiomed.com/content/6/1/4
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ited available drug options. Supposing that tmk levels fol-
low a quadratic curve as above, parallel to the "S" growth
curve of microbes, then this AUC can be calculated as the
integral (∫) of the equation: |tmk| = at2+ bt + c or simply
1/3 at3+1/2 bt2+ct. From this equation, it can also be
derived that the drug sensitivity of tubercle bacilli is an
inverse factor of the AUC while existing resistance profiles
are directly correlated to the same Area. However, in order
to compare the prevailing resistance profiles between two
isolates, one would need first to define the time over
which to make the above calculations (say t1-t2); although
we recommend that future universal algorithms be based
on the AUC between t = 0 and the t-value when the tmk
levels first reach the stationery stage. Note also that TMK-
myc assays have the advantage of being applicable to all
drug scenarios without the need for modifications such as
those required for colorimetric redox-indicator methods
or nitrate reductase assays, which have been found to be
highly sensitive only for rifampicin and isoniazid resist-
ance testing [9]. Moreover, targeted detection of other
related microbial enzymes such as HIV thymidine kinase
may enable drug resistance profiling for HAART to be con-
ducted within resource-limited settings, where inexpen-
sive platforms for phenotyping or genotyping for drug
sensitivity have remained mostly lacking [22]. In the case
of the M.tb scenario, whether or not the proposed TMK-
myc-based drug profiling assay would yield consistent
results relative to several existing rapid drug resistance
tests such as phage amplification, or line probe assays
such as INNO-LipA Rif.TB(LiPA) or Genotype MTBDR, is
a subject that requires future comparative evaluations
once TMKmyc assays are in practical use [9].
Several limitations are evident in our theoretical model,
which must be dealt with prior to the actualization of
TMKmyc assays as a predictive biomarker for in vitro
tubercle bacillus growth. First, it is currently unclear
whether secreted TMKmyc is present in the culture
medium at levels detectable by MAb(s). Specifically, exist-
ing data provide contradictory views about the possible
secretory nature of TMKmyc. Munier-Lehmman et al. [18]
have previously shown that TMKmt forms over 30% of all
colony filtrate proteins in a strain of E. coli genetically
engineered to express TMKmt. However, other studies on
host sera using in vivo-induced antigen technology (IVIAT)
[23-25] and crossed immunoelectrophoresis (CIE) [26],
though identifying over 11 genes involved in M.tb metab-
olism, do not categorically list TMKmt among them. Note,
however, that the absence to date of methods for specific
monitoring of TMKmyc (such as the one we propose)
among the latter studies [[23-25] and [26]] relative to
work by Munier-Lehmann and colleagues [18] may possi-
bly explain these discrepancies. Second, it is assumed that
TB cultures constitute a homogenous mixture of actively
proliferating cells. Within wild type M.tb cultures, how-
ever, this may not be the case as active and dormant tuber-
cle may co-exist. Such heterogeneity of growth among the
M.tb in culture may also affect TMKmyc secretory levels.
We hold that since qualitative rather than quantitative
measures of TMKmyc are required to determine M.tb cul-
ture positivity, TMKmyc-based assays are still valid for the
purpose of reducing time-lines to the reading of TB cul-
tures. What may be affected is drug resistance profiling,
since this requires measurement of the levels of TMK in
the culture. Therefore, for purposes of drug resistance pro-
filing, more algorithms may need to be integrated into the
TMKmyc assays to render them more standardized and
reliable in the face of heterogeneity of M.tb proliferation
in vitro. Third, in the absence of in vitro evidence to sup-
port the view that TMKmyc may be adequately and specif-
ically detected by monoclonal antibodies, the proposed
assays for TMKmyc levels in culture are still speculative.
Whether TMKmyc-based assays will perform better than,
worse than or the same as existing TB tests [10] therefore
remains elusive and requires future comparative clinical
trials. More work needs to be done to affirm the binding
affinity and specificity of the antigen capture assays for
TMKmt. This work is, however, complicated by the find-
ings by Steingart and colleagues, who recently reported
inconsistencies in most commercially available TB serodi-
agnostics [16]. Fourth, although it is clear that DNA
duplication precedes actual microbial division [17], the
duration of this process among various microbes includ-
ing M.tb is largely unclear. Studies such as that by Sherley
and Kelly [19] are therefore needed for M.tb and other
infectious pathogens alike. Overall, if the above-listed
potential shortcomings are overcome, the proposed anti-
body-based TMKmyc assays provide the flexibility to be
mounted on a cheap technology platform for use within
resource-limited settings. For instance, incorporation of
"chemiluminiscent or fluorescent" strategies may enable
"photo-detection of TMKmyc changes in culture" and
thereby automation of the entire assay. Specifically, if the
initiation of light emission is tailored to antigen (TMK-
myc) capture, then chemiluminiscent or fluorescent TMK-
myc-specific antibodies (CAbs and FAbs respectively) may
be integrated within the LJ medium so that visual obser-
vation of color change or photometric measurements may
be used to detect the levels of TMKmyc secreted. This sim-
ple automation could remove the need to conduct labori-
ous quantitative ELISA or antigen capture assays to
monitor TMKmyc levels, and thereby allow use by persons
without extensive specialized training. Lastly, as TMKmyc
is a specific antigen of M.tb [18], targeted detection of
TMKmyc in sputum may provide an alternative strategy
for diagnosing symptomatic TB to that based on staining
for AFBs.
Conclusion
TMKmyc assays may be applicable to reducing time-lines
to determining positivity of Mycobacterium tuberculosis
(M.tb). Moreover, TMKmyc assays may also serve to has-Publish with BioMed Central    and   every 
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ten drug resistance profiling in vitro. The inherent flexibil-
ity of the proposed antigen capture assay allows the
potential incorporation of simple technologies such as
chemiluminiscent or fluorescent strategies and could ena-
ble easy-to-use platforms to be built such as those based
on "photo-detection of TMKmyc changes in culture", as
well as automation of the entire assay.
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